Fig. 4

Subclonal ANK1 mutation-driven transcriptional effect is associated with the level of immune cell infiltration in CRC. A ANK1 subclonal mutation-driven genes affect multiple important biological pathways. B, C Spearman correlations between of ANK1 subclonal mutation, ANK1-driven genes and immune cells across human using TISIDB, TIMER and GEPIA. D Differential expression of IDO1, IGNG, IL4I1 and MAPK12 among CRC patients with clonal ANK1 mutation (yellow), subclonal ANK1 mutation (gray), and ANK1 wide type (blue). E Expression levels of ANK1 and MAPK12 in CRC patients in relation to response to chemotherapy treatment. Patients were classified as responder or nonresponder according to the 5-year relapse-free survival. P-value is calculated using Mann–Whitney test. F The significant difference of INFG expression between responders (68 samples) and non-responders (230 samples) in urothelial cancer patient cohorts with PD-L1 blockade cancer immunotherapy. G correlation of PD-L1 and ANK1-driven genes in colon cancer types